Results 1 to 10 of about 1,321,865 (276)
Gut and Liver, 2011 The goal of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection is to attain a sustained virologic response (SVR), which is defined as undetectable serum HCV-RNA levels at 6 months after the cessation of treatment.
Raymond T. Chung, Jae Young Jang
doaj +4 more sources
Chronic Hepatitis C with Cyanosis [PDF]
Case Reports in Hepatology, 2019 Background. There are multiple aetiologies for dyspnea in patients with liver disease, including pneumonia, pulmonary embolism, hepatic hydrothorax, portopulmonary syndrome, and hepatopulmonary syndrome.
Mahmood Alawainati +3 more
doaj +2 more sources
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C [PDF]
New England Journal of Medicine, 1998 BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b
Albrecht, Janice K., , Ph.D. +9 more
core +3 more sources
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir [PDF]
Swiss Medical Weekly, 2012 Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of
Darius Moradpour +2 more
doaj +3 more sources
Natural history of chronic hepatitis C [PDF]
Hepatology, 2002 Much controversy surrounds the issue of the natural history of hepatitis C virus (HCV) infection. Many authorities view the disease as inexorably progressive with a high probability of advancing over time to cirrhosis and occasionally hepatocellular carcinoma (HCC) and, therefore, likely to be responsible for causing death ...
L. Seeff
semanticscholar +5 more sources
Chronic hepatitis C: future treatment
Clinical Pharmacology: Advances and Applications, 2014 Astrid Wendt, Xavier Adhoute, Paul Castellani, Valerie Oules, Christelle Ansaldi, Souad Benali, Marc BourlièreDepartment of Hepato-Gastroenterology, Hôpital Saint-Joseph, Marseille, FranceAbstract: The launch of first-generation protease ...
Wendt A +6 more
doaj +6 more sources
Atherosclerosis and chronic hepatitis C
Annals of Hepatology, 2012 Luis D. Carrillo-Córdova +2 more
doaj +4 more sources
The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019
Frontiers in Public Health, 2023 Background and aimHepatitis C virus infection can lead to an enormous health burden worldwide. Investigating the changes in HCV-related burden between different countries could provide inferences for disease management.
Jia Yang +7 more
doaj +1 more source
BMJ, 2007 Hepatitis C infection is a treatable disease.1 Generally, people with chronic hepatitis C are relatively asymptomatic but risk progression over time to cirrhosis and its complications. Combination antiviral therapy with pegylated interferon and ribavirin achieves sustained virological response rates of 42-80% depending on genotype.2 In August 2006 the ...
Timothy J.S. Cross +2 more
openaire +3 more sources
Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections
Scientific Reports, 2022 The direct impact of chronic hepatitis B and hepatitis C on neurocognition remains elusive due to the frequent comorbidities, and the domains of the neurocognitive functions affected have rarely been investigated comprehensively.
Chun-Hsiang Tan +9 more
doaj +1 more source